2iB Partners (Singapore) and TMA Group (US) agree on US-Asia Pacific Partnership

2iB Partners (Singapore) and TMA Group (US) agree on US-Asia Pacific Partnership

  • 2iB Partners can now offer market access to clients into the US

  • TMA Group can now offer market access to clients into Asia Pacific

  • Partnership to increase and facilitate US-Southasia M&A

 

26th January, 2018 – 2iB Partners and TMA group announced a partnership to provide clients with increased market access and network, now offering market access into United States (US), United Kingdom (UK), Australia, India, China and Southeast Asia. To enhance collaboration between the 2 companies CEO of TMA Group, Mr. Kishore Mirchandani will be appointed Head of US in 2iB Partners and Managing Director of 2iB Partners, Mr. Yang Yen Thaw will be appointed Head of Asia Pacific in TMA Group.

 

“Both companies are extremely complementary and a 2 way partnership will not only enhance 2iB Partner’s range of service offerings to clients but also give our clients the opportunity to leverage on an extended network of trusted partners in the US. Likewise, TMA Group clients in the US can now leverage on 2iB Partners to gain market access into South Asia. This network and expertise is vital in any company’s internationalization plan. From a cross-border M&A perspective, the partnership will also help increase and facilitate US-Southasia M&A activity. Both teams have had extensive experience in handling M&A transactions in different jurisdictions but with ready man-on-ground presence in those countries, these can greatly facilitate post-M&A integration work.”

-Director and Chief Operating Officer, 2iB Partners, Mr. Dylan Tan.

 

“There has been a tremendous shift in the way companies are defining their growth strategies and we’ve been deeply involved in conversations with our clients about globalization. Borders are no longer barriers to seek out new customers whether its in Financial Services or ECommerce and we strongly believe that our partnership with 2iB Partners will bring value to our clients looking to expand. There is an alignment in the way we work and the clients we serve.”

 – CEO, TMA Group, Mr. Kishore Mirchandani.

 

About TMA Group

TMA Group is a leader in fractional C-Suite advisory services, specifically focused on the CFO, CMO and CIO specialities. Each of our results-oriented, seasoned executives have 20+ years of experience ready to advise businesses on strategy, growth plans or to address specific challenges and opportunities. As extended members of your team, our executives and support members offer the flexibility you need with the urgency your business demands.

 

About 2iB Partners

2iB Partners is a specialist M&A and business consultancy that has a strong presence in Southeast Asia, China, India and UK. 2iB Partners provides M&A deal flow to buy-side companies and also provides ad-hoc entrenchment of highly qualified professionals and business veterans. A strong network of trusted partners in Marketing, Technology, Business Process Outsourcing, Organizational development and C-suite personnel allows for a full suite of services right from advising to implementation.

2iB Partners has extensive networks with strategic buyers, MNCs, listed companies, investment networks and funds from US, UK, China, Philippines, India, Vietnam, Myanmar, etc.

In addition to the above, 2iB Partners also takes up a strategic role for companies outside of the Southeast Asian locale for market entry using Singapore as a gateway. Conversely, 2iB Partners also help companies expand into countries out of Asia, utilizing a trusted network of partners.

 

2iB Partners in brief

2iB Partners is a specialist M&A and management consultancy firm that has extensive networks with strategic buyers, MNCs, listed companies, investment networks and funds from US, UK, China, Philippines, India, Vietnam, Myanmar, etc.

2iB Partners help companies scale up and internationalize through inorganic growth, joint ventures or management consultancy. Through Singapore as a strategic base, 2iB Partners helps companies outside of Asia gain market access and companies in Asia expand internationally and regionally. 2iB Partners also provide ad-hoc entrenchment of highly qualified professionals and experienced businessmen to solve complex business problems through experience and insight.

For partnerships, speaker and general business enquiries with 2iB Partners:

Contact Person Dylan Tan
Designation Chief Operating Officer
Email Dylan@2ibpartners.com

YOU MAY LIKE

M&A – The Legal Angle

M&A - The Legal Angle The solution and problem in a merger or acquisition is regulatory in nature. In all cross-border deals, there is no go-around to regulations. Laws are enacted to essential protect life and property of its citizens. Therefore, it will...

read more

Why M&As Go Wrong

Acquisitions that are rushed can result in problems and challenges after closing in a transaction: Some of the reasons why M&As go wrong are:   1. Assumption Asymmetry Leaders and owners may over value a target by making assumptions including...

read more
2iB Partners Welcomes Chairman of Eu Yan Sang International, Richard Eu as Adviser

2iB Partners Welcomes Chairman of Eu Yan Sang International, Richard Eu as Adviser

SINGAPORE – 20th November, 2017 – 2iB Partners proudly welcomes Richard Eu as adviser and part of its team. Richard brings an invaluable wealth of experience having grown a small company into one of Asia’s largest Traditional Chinese Medicine groups today.

Richard Eu was appointed to the board as Chairman of Eu Yan Sang International (“EYSI”) board on 1st of October 2017. He leads the board in providing governance oversight, deliberating the Group’s strategic choices and providing independent counsel and advice to the Group Chief Executive Officer (“CEO”). Richard joined the business in 1989 and was appointed Group CEO of EYSI in 2002. He has been instrumental in transforming it into one of Asia’s largest Traditional Chinese Medicine (“TCM”) groups today. EYSI was listed on SGX from 2000 to 2016.

EYSI is a company that specializes in traditional Chinese medicine since 1879. It currently runs more than 300 retail outlets in Hong Kong, Macau, China, Malaysia, Singapore, and Australia, plus two factories in Hong Kong and Malaysia. The group also operates over 30 TCM clinics in Malaysia, Singapore and Hong Kong.

Richard was named the Ernst & Young Entrepreneur of the Year 2011 (Singapore) and represented Singapore at the Ernst & Young World Entrepreneur of The Year 2012 award in Monte Carlo, Monaco. He was also recognized as the CEO of the year by the Singapore Corporate Awards 2010, for SGX-listed companies with a market capitalization of under S$300 million. In 2016, he was lauded as the Brand Leader of the Year by InfluentialBrands. Richard holds a Bachelor of Law degree from the London University, UK and has worked in merchant banking, investment management, stock broking, computer distribution, and venture capital.

He actively participates in community projects and non-profit organizations. He serves as Chairman of the National Museum of Singapore and Singapore University of Social Sciences and is on the board of Thye Hua Kwan Moral Charities Limited. He also sits on the boards of other companies.

 

Message from Managing Director, Mr. Yang Yen Thaw:

 

“It is our privilege and pleasure to welcome Richard as our friend and Adviser to our panel of experts to assist clients in their business. Be it from growing as a small company to family businesses or scaling up as an SME to valuable advice on listed companies. Our clients will benefit immensely from his insights and extensive experience.”

 

Message from Director, Mr. Dylan Tan:

 

“Richard is someone who has achieved great success in the business world and is undoubtedly one of the representatives of Singapore brands. He also has a strong passion for keeping Singapore brands alive. Needless to say, he brings a wealth of experience and can provide invaluable advice to the companies we work with. This ties in greatly with our aim of helping Singapore small and medium enterprise (“SMEs”) scale up and internationalize. – Of course, he is also, literally, a rock star.”

2iB Partners in brief

2iB Partners is a specialist M&A and management consultancy firm that has extensive networks with strategic buyers, MNCs, listed companies, investment networks and funds from US, UK, China, Philippines, India, Vietnam, Myanmar, etc.

 

2iB Partners help companies scale up and internationalize through inorganic growth, joint ventures or management consultancy. Through Singapore as a strategic base, 2iB Partners helps companies outside of Asia gain market access and companies in Asia expand internationally and regionally. 2iB Partners also provide ad-hoc entrenchment of highly qualified professionals and experienced businessmen to solve complex business problems through experience and insight.

 

For partnerships, speaker and general business enquiries with 2iB Partners:

Contact Person Dylan Tan
Designation Chief Operating Officer
Email Dylan@2ibpartners.com

YOU MAY LIKE

M&A – The Legal Angle

M&A - The Legal Angle The solution and problem in a merger or acquisition is regulatory in nature. In all cross-border deals, there is no go-around to regulations. Laws are enacted to essential protect life and property of its citizens. Therefore, it will...

read more

Why M&As Go Wrong

Acquisitions that are rushed can result in problems and challenges after closing in a transaction: Some of the reasons why M&As go wrong are:   1. Assumption Asymmetry Leaders and owners may over value a target by making assumptions including...

read more

[Video] 2iB Partners Speaks at Southeast Asian M&A and Corporate Investment Conference 2017

[Video] 2iB Partners Speaks at Southeast Asian M&A and Corporate Investment Conference 2017

In the above video, Managing Director of 2iB Partners, Mr. Yang Yen Thaw delivers a 50 minute speech on Legal issues in cross-border Mergers & Acquisitions (M&A) and a new approach to M&A.

2iB Partners formed part of a repertoire of experts hailing from MNCs, mainstream banks, advisory firms and funds with substantial AUM.

 

 

Speaker line-up included:

Sanjay Mathur Chief Economist – Southeast Asia and India ANZ Bank
Sikh Shamsul Ibrahim Investment Director Malaysian Investment Development Authority (MIDA)
Greg Ohan Director Jones Lang Laselle, Vietnam
Hector Wang Investment Director China-ASEAN Investment Cooperation Fund
Edwin Vanderbruggen Senior Partner VDB Loi Co.,Ltd
Jonathan Fein Vice President BDA Partners
Ryoichi Nishizawa Head of M&A Advisory Mitsubishi Corporation
Yang Yen Thaw Managing Director 2iB Partners
Kevin Murphy Managing Director Andaman Capital Partners

Panelists include:

Kate Holgate Partner and Head Brunswick Singapore
Aaron Howell Managing Director Rothschild
Robert Rosen Co-CEO Kenon Holdings
Kala Anandarajah PBM Head Competition & Anti-trust and Trade Rajah & Tann
Dag Ove Solsvik Head of Group Legal, Middle East and APAC DNV.GL

The room was filled with more than a hundred people representing big listed companies, billion dollar funds and conglomerates from all sectors taking a strategic interest in the Southeast Asian region.

 

Mr. Yang Yen Thaw addressing “Why M&As go Wrong”.

Legal strategy in M&A

Mr. Yang Yen Thaw engaging the audience in an open floor discussion. CoAggregation® in action!

Message from the Director:

2iB Partners continues to build its reputation and broaden international networks with MNCs, strategic buyers, listed companies, funds and networks in US, UK, China, India, Phillipines, who have taken a strategic interest in the Southeast Asian market. We also understand that there are a significant number of small and medium enterprises (SMEs) in the region that are looking to scale up and regionalize in SEA or gain market access into China.

With regards to these 2 different channels of companies, we have the appropriate networks and expertise to assist them with their expansion plans whether through joint ventures, inorganic growth or general business consultancy. We see ourselves in a strategic position to assist these stakeholders in their internationalization and growth plans in or out of the region through Singapore.

From a macroeconomic perspective, the ASEAN story is generally positive and is one of the fastest growing regions with projected 4.9% GDP growth this year compared to projected global growth of 3.5%. Fast growing Myanmar is also projected for a growth of 7.5% next year, though for this country, regulations may slow the advancement of certain sectors. The ASEAN growth is projected to outperform that of global growth rate for the foreseeable future with relative political stability and increased connectivity in terms of both investment and trade.

Global trade has also re-emerged and as a result, Asia, that is the most export dependent has benefited substantially. Indicators suggest that domestic demand is also improving post slow down but it would take awhile before this reaches a steady state. This could suggest investment opportunities in the medium to long term.

Inflation is behaving and the region as a whole is not sitting on any large imbalances. Therefore, with regards to concerns on fed hikes, as long as they are well introduced and earnings growth is faster than the rise in cost of capital, we should sift through the shifts in global monetary conditions.

The ASEAN Economic Community (AEC) blueprint which aims for tax collaboration by 2025 and reduction in trade transaction cost by 2020 also point to significant improvements in opportunities.

-Data from FocusEconomics and World Economic Outlook.

Last but not least, we would like to express our thanks to Mr. Tony Huang and ValueTang LLC and look forward to greater and deeper collaboration in time to come.

 

Dylan Tan

2iB Partners – Director

 

 

For partnerships, speaker and general business enquiries with 2iB Partners:

Contact Person Dylan Tan
Designation COO
Email Dylan@2ibpartners.com

YOU MAY LIKE

M&A – The Legal Angle

M&A - The Legal Angle The solution and problem in a merger or acquisition is regulatory in nature. In all cross-border deals, there is no go-around to regulations. Laws are enacted to essential protect life and property of its citizens. Therefore, it will...

read more

Why M&As Go Wrong

Acquisitions that are rushed can result in problems and challenges after closing in a transaction: Some of the reasons why M&As go wrong are:   1. Assumption Asymmetry Leaders and owners may over value a target by making assumptions including...

read more
Panelist Commentary on Fintech in Healthcare: Partnerships & Regulatory Frameworks – 27 October 2017

Panelist Commentary on Fintech in Healthcare: Partnerships & Regulatory Frameworks – 27 October 2017

A commentary by Yang Yen Thaw on his views in the panel discussion on Accelerating Innovation: Partnerships & Regulations on the topic “Fintech in Healthcare”. The panelists were Yang Yen Thaw, Managing Director of 2iB Partners, Astrid S. Tuminez, Regional Director, Corporate, External, and Legal Affairs at Microsoft Southeast Asia, Wayne Chia from Asia P3 Hub and Azmul Haque, Managing Director of Collyer Law.

The Fintech for Health event was organized by ACCESS Health International.

 

Accelerating Solutions: Co Industry Innovation and Public Private Partnerships for Health Regulatory Frame Works for the Integration of Fintech and Digital Health

This commentary deals with the talk on Fintech in Healthcare conducted by ACCESS Health International Southeast Asia Pte Ltd – Accelerating Solutions: Co Industry Innovation and Public Private Partnerships for Health Regulatory Frame Works for the Integration of Fintech and Digital Health. The questions it sought to address were – Co-industry partnerships and public private partnerships are the way forward. How can new partnership models accelerate adoption of new technologies and business models? How does a partnership move from idea stage to execution stage, in a way that is beneficial to all parties involved? What factors increase the likelihood of a successful partnership?

 

Fintech in Healthcare: Introduction

Fintech is basically an intersection of financial services and technology. Fintech aims to deliver a seamless user experience both in terms of anytime access to finance and automated payments through the omnipresent mobile phone. Fintech seeks to address opacity, complexity, lack of competition, poor business culture, or high operational costs. It aims to apply disruptive technology to traditional handling of finance, transfers and payments. Further, new technology like blockchain and crypto/virtual currencies have the potential to reduce the cost of and replace transacting in a financial system. Aggressive enforcement of laws, money transmission and other regulations represents an ongoing threat to FinTech companies.

The future of fintech depends on ability to withstand competition from global banks, adaptability by smaller fintech companies and to regulatory framework.

Healthcare can be addressed in several ways. It covers the maintenance, care and restoration of health of body and mind and the process, procedures and methods thereof. Healthcare seeks to prevent, diagnose and treat health issues. Healthcare varies across countries, groups, and individuals and is influenced by social, economic and regulatory conditions. According to the World Health Organization (WHO), a well-functioning healthcare system requires a robust financing mechanism; a well-trained and adequately paid workforce; reliable information on which to base decisions and policies; and well-maintained health facilities and logistics to deliver quality medicines and technologies.

However, the future on healthcare will also be more focussed on the distinctions between healthcare and sickcare, wellness and fitness, patientcare and doctorcare. Healthcare as a matter of opinion is most often 95% doctor care and 5% treatment. So, while regulation of the 5% can cover technology and healthtech, the 95% should be around post-technology and can be a focus for fintech.

 

Of legal and regulatory matters relating to Fintech

Though there are no specific laws to govern fintech, legal application would be in the form of the individual laws themselves i.e., laws relating to finance and technology respectively. Further, laws that affect fintech are – data security and privacy, consumer protection, AML, ATF, insurance and securities. Complications will further arise when there are cross-border transactions.

The other issues that fintech face are sharing and storing of information. Control of information and its flow on personal mobile devices, coupled with sharing over cloud and other common platforms and storage platforms, may require additional security measures by law. Some countries provide approved cloud storage providers. While these do not solve data and security issues, it does mitigate some of them.

Fintech is proceeding at high speeds. As most laws play catch up as well as regulate established practices, regulating fintech is a very difficult process. Besides, it is not efficient to introduce laws and regulations in an industry where disruptive technologies themselves face danger of becoming obsolete or replaced by newer technologies.

 

Of legal and regulatory matters relating to healthcare

Healthcare policies is influenced by social, economic and regulatory conditions of a country and varies across organizations, groups, and individuals. Whether healthcare is a matter of public or private service is also a factor when determining regulations. In many countries, the issue of regulating indigenous or alternative healthcare play a significant role in addition to regulatory treatment relating to homeopathy and allopathy practices. For instance, traditional Chinese medicine, acupuncture, holistic medicine, Ayurveda are examples some of indigenous and accepted healthcare.

There are various agencies that regulate public and private healthcare at different levels. Private organizations also participate in the regulations by providing accreditation, rankings, certification and additional oversight. Areas covered include practitioners and facilities, information flow, legal compliance, safety and other areas in the healthcare industry. Regulations of other regulatory departments are also pertinent such as regulations relating to food and drugs, disease control and prevention and environment.

All areas of healthcare, including physicians, medical directors, healthcare computer technology companies, healthtech, healthcare facilities and pharmaceutical companies, are subject to regulatory review and compliance.

 

Fintech in Healthcare

Areas where fintech in healthcare, public and private, exist or have possibilities are in finance, funding, payments and other monetary issues in healthcare. In developed countries, healthcare will not be provided unless there is “proof of payability”. In developing and underdeveloped countries, “right to life” does not include passage to good healthcare in the Golden Hour.

There are many ways to tie in fintech to healthcare, but this involves active tri-partite participation between Government, healthcare and finance institutions. A tech product that “talks” to these institutions or provides an appropriate platform will improve and provide a more congenial regulatory environment.

Fintech generally covers the following of which many are applicable to healthcare.

  1. Banking infrastructure
  2. Healthcare lending
  3. Consumer lending
  4. Consumer Payments
  5. Crowdfunding for healthcare projects
  6. Equity financing in healthcare projects
  7. Financial healthcare research and data
  8. Financial transaction security in healthcare
  9. Institutional investing in healthcare
  10. International money transfer
  11. Payments backend and infrastructure
  12. Personal finance, insurance in healthcare
  13. Point of sale payments

Some finance services in healthcare cover:

  1. Lending services
  2. Remittance services
  3. Personal finance services
  4. Litigation financing – for doctors and patients alike (medical negligence)
  5. Banking services
  6. Crypto and virtual currencies (substitute funding and alternate payments)

Some payments in healthcare cover:

  1. Out-patients or walk-ins in clinics (daily basis)
  2. In-patients (depending on duration of stay – predictable)
  3. Critical patients (whose duration of stay – unpredictable)
  4. Operative patients (costs – variable)
  5. Wellness clinics (periodic basis)
  6. Geriatric patients (neglected group)
  7. Road traffic patients (identifiable/Good Samaritan based)
  8. Psychiatric patients (may/may not generate income)
  9. Pathology labs (investigations/reports)
  10. Ambulance services (emergency services)
  11. Medicines (delivered at home)
  12. Home-services (post op dressing/health monitoring)

The other related areas for fintech in healthcare are:

  1. Payroll to ancillary staff such as ambulance drivers
  2. Independent healthcare related professionals – medical representatives
  3. Cost monitoring for medical supplies
  4. Third party private healthcare – nurses, hospices, private nursing
  5. Technologies like Blockchain are also potential platforms that bring fintech and healthcare together
  6. Medical litigation financing
  7. Medical negligence cover
  8. Insurance

Some payment services currently operating in healthcare:

  1. Payment gateway providers
  2. POS payments-point of sale-maybe on premise or cloud based
  3. Credit payments
  4. Services running on credit – via banks
  5. Mobile apps
  6. Integrated mobile and browser apps

Of legal and regulatory matters relating to fintech in healthcare

The objective of both fintech and healthcare regulation is to protect the consumer or end user. In most jurisdictions, there is hardly any government agency to integrate any planning, financing, policy making or drafting any legislation relating to fintech and/or healthcare. Though there are no specific laws to govern fintech and healthcare, legal application would be in the form of the individual laws themselves i.e., laws relating to healthcare, finance and technology.

While consideration of legislation and law-making, life and property are given paramount importance. Therefore, most laws and regulations in these areas are stringent. Given that healthcare and fintech are primarily these areas, one can expect higher compliance and due diligence. In addition to specific laws governing healthcare and fintech, combined issues of personal data on finance, health statistics and privacy of individuals need to be considered. Healthcare privacy would also include right to be or not to be treated.

Regulatory approaches will fail to cope with the rapid pace of innovation in fintech and healthcare due to speed of development. It is not possible for regulations to imagine technological advances and introduce anticipatory laws and if regulations are considered with restrictions on a reactionary basis; that would stifle innovation in fintech and healthcare. In the financial crisis of 2008, the introduction of the Dodd Frank Wall street Reform actually galvanized small fintech companies to innovate and disrupt the financial system. It is much harder to regulate these companies. Big banks, in a bid to limit risk and compliance, many times outsourced financial services to these companies who would find ways to skirt regulation and compliance.

Progress in electronic pricing and trading technologies will enable fintech companies to even weave an inextricable web of derivative transactions in healthcare. It is not difficult to image fintech in healthcare bringing in instruments where medical and healthcare loans could be repackaged into instruments such as healthcare backed securities, collateralized debt obligations, credit default swaps and other second order derivative structures. Regulation challenges would be compounded. Tech companies could take advantage as negative fast and first movers to go into financial and healthcare/healthcare areas where there is no existing regulation. Many such companies also carry a very low asset to equity ratio and since they take advantage of the fact that transactions move at high speeds and low costs, they may even close down at the first hint of regulation with no option of recourse left to the user.

 

Public Private Partnership – Regulatory Possibilities

Fintech in healthcare will have different applications in different countries. In an ideal world, there should be universal laws that are common and govern countries universally. But this is not possible under the current geo-political climate. Each country will have a unique approach towards regulating healthcare and fintech. With borderless and seamless deployment of tech products, cross-border regulation is highly complex.

 

Regulatory Sandbox

The objective of a regulatory sandbox is to construct a well-defined space, for a limited duration, within which companies can experiment with innovative tech solutions in a relaxed regulatory environment and with the support of a national regulator. Rather than preventing failure, a regulatory sandbox seeks to provide appropriate protections to limit impact of failure. Regulatory sandbox itself is an innovation of sorts and have been around only for the past few years. UK FCA reports success in meeting its overall objective of reducing time and cost of getting innovative ideas to market.

Regulatory sandboxes may work well in a country such as Singapore where its citizens and corporates comply with the law. Similarly, the regulatory sandbox can be deployed in states or provinces within a country that have a strict adherence or zero tolerance to legal violations. It will also work well with established companies and big players. In fact, some regulatory sandboxes have a minimum financial entry level requirement. However, in many jurisdictions, individuals and smaller companies may prefer the open market. Some companies may explore loopholes that the current regulatory climate provides and exploit them. There is no assurance that these loopholes will be revealed in a sandbox. Some businessmen will operate on the premise that it is easier to seek forgiveness than permission from regulators. Where the regulatory sandbox is intended to be for toddlers to swim around before entering the ocean, the pool itself may be infested with sharks. A regulatory sandbox prima facie appears to appeal more to the regulators who want to analyse and understand a new environment and therefore prepare regulations and paperwork. The sandbox itself may not provide a live environment or appropriate market size to test the product. Almost like applying what an individual studied in school or college to real life. Plus, there is the perceived danger of a company believing it is on a virtual watchlist if it fails in the sandbox. Further, even if the company passes the sandbox, it may decide against deploying the product in that country.

Having said all that, the advantages of a regulatory sandbox are – equity financing and higher probability of receiving investments due to perceived regulatory compliance, speed to market, more reliable financial innovation to the consumer, understanding a local regulatory climate as well as the process – its ease or difficulty – in obtaining a licence or approval.

 

Self-regulation

Self-regulation by fintech companies in healthcare may be considered as an alternative. However, self-regulation must contain a caveat in that the regulators’ approval need to be obtained before deployment. The difference is operating in a live and an international market as well. Self-regulation can commence with intent of compliance by setting out internal policies, rules and regulations. Government can provide guidelines and principles. This collaboration can bring about corporate policies which may contain:

  • Management and personnel management, training, systems and controls
  • Scope of direct and indirect liability of product and outcomes
  • PR, sales and marketing processes; representations made
  • Standard terms and conditions
  • Statutory and regulatory compliance
  • Systems and control processes periodic review

Consequences of non-regulatory compliance would include regular regulatory scrutiny, criminal penalties and civil sanctions, public announcements.

Many fintech entrepreneurs are seasoned. By not limiting functions of a fintech company within a “sandbox” and without the fear of big brother watching directly, fintech companies can be allowed freedom and innovation. By limiting fast and immediate exposure to the market by the aforementioned collaboration, the regulators can anticipate potential problems with the fintech product. The friendliness of the regulator can be displayed in the approach to the self-regulation.

Private public interaction and collaboration should further focus on the following:

  • Help craft consistent, thoughtful regulation for fair use of products
  • Reduce inconsistencies in the scope and application of local regulations (state, province)
  • Standardization of regulatory and supervisory expectations
  • Advancing policy initiatives
  • Coordination between regulators themselves.
…and last but not least, a mandatory selfie with Astrid S. Tuminez, Regional Director, Corporate, External, and Legal Affairs at Microsoft Southeast Asia, Wayne Chia from Asia P3 Hub and Azmul Haque, Managing Director of Collyer Law!

For partnerships, speaker and general business enquiries with 2iB Partners:

Contact Person Dylan Tan
Designation COO
Email Dylan@2ibpartners.com

YOU MAY LIKE

M&A – The Legal Angle

M&A - The Legal Angle The solution and problem in a merger or acquisition is regulatory in nature. In all cross-border deals, there is no go-around to regulations. Laws are enacted to essential protect life and property of its citizens. Therefore, it will...

read more

Why M&As Go Wrong

Acquisitions that are rushed can result in problems and challenges after closing in a transaction: Some of the reasons why M&As go wrong are:   1. Assumption Asymmetry Leaders and owners may over value a target by making assumptions including...

read more

2iB Partners to speak at ACCESS: Fintech For Health Conference 26-27 October, 2017

2iB Partners to speak at ACCESS: Fintech For Health Conference 26-27 October, 2017

2iB continues to play an active role in advising on the various business ecosystems and how different sectors can engage with each other seamlessly.

As part of the panel of experts, Mr. Yang Yen Thaw, Managing Director of 2iB Partners will be speaking at the Fintech For Health Conference on “Accelerating innovation: Partnerships and regulatory frameworks for the integration of fintech and health tech” as part of a 30 minute panel discussion with veteran lawyers on regulatory frameworks.

 

FINTECH FOR HEALTH

Fintech for Health is a high level conference exploring key opportunities at the intersection of fintech and health tech. We are bringing together people and partners from across sectors to envision healthcare of the future— one that is patient centered, high quality, affordable, and accessible. We will explore how the integration of fintech with digital health technologies, such as blockchain and artificial intelligence, can result in improved healthcare access and quality, across resource poor to resource rich settings.

Hear from experts on real world health systems challenges and the innovative approaches that companies and governments are using to tackle them. Explore the role of deep technology in making health financing more secure and efficient. Meet like minded individuals and organizations across industry, development, and government who are committed to outcomes and impact.

 

Registrations open at http://fintechforhealth.com/

For partnerships, speaker and general business enquiries with 2iB Partners:

Contact Person Dylan Tan
Designation COO
Email Dylan@2ibpartners.com

YOU MAY LIKE

M&A – The Legal Angle

M&A - The Legal Angle The solution and problem in a merger or acquisition is regulatory in nature. In all cross-border deals, there is no go-around to regulations. Laws are enacted to essential protect life and property of its citizens. Therefore, it will...

read more

Why M&As Go Wrong

Acquisitions that are rushed can result in problems and challenges after closing in a transaction: Some of the reasons why M&As go wrong are:   1. Assumption Asymmetry Leaders and owners may over value a target by making assumptions including...

read more
2iB Partners to join panel of experts to speak at Southeast Asia M&A Corporate Investment Conference 2017: 2-3 November

2iB Partners to join panel of experts to speak at Southeast Asia M&A Corporate Investment Conference 2017: 2-3 November

In this event, Managing Director, Yang Yen Thaw of 2iB Partners will join a panel of other experts to speak on cross-border M&A in South East Asia. 2iB continues to strengthen and develop it’s presence and network in cross-border M&A through strong synergistic partnerships with key players. 

 

EXPLORING CURRENT TRENDS & STRATEGIES FOR

INVESTMENT AND M&A IN SOUTHEAST ASIA

Southeast Asia is a dynamic market with nearly 700 million people, now this region is becoming the world’s most attractive destination for foreign investment. Greenfield investment and M&A activities increased rapidly in the past five years in this region. A lot of multinational companies are increasing the investments in this region due to the cost advantage and continuous opening policy, SEA now receives more foreign direct investment than China. Meanwhile, China is shifting the role from an investee to an outward investor. Following the ‘One Belt, One Road’ plan, China will become another big investor in Southeast Asia besides Japan. For multinational companies, how to capture the potential direct investment and M&A opportunities and managing their investment portfolios and maximize long-term value? And how to meet the legal, finance and culture challenges for the cross-border investments, these are very rich and interesting topics.

This year’s Southeast Asia Corporate Investment Merger & Acquisition Conference 2017 will be held in Singapore. This conference is an exclusive event for the corporate executives from the global multinational corporations to learn the latest trends and regulations affecting the cross-border investment in Southeast Asia. The event is also a valuable opportunity for business networking by exchanging the practical experience and lessons of direct investment, M&A, JV partnership in this region. Senior executives from MNCs, PE, VC and professional advisors for finance & tax, legal, management consulting, investment banking will join this year’s exciting event. We are looking forward to your participation!

 

 

 

Speaker list:

Speaker Details
Mr. Angelo Dell’ Atti Global Head, Corporate Finance, IFC (International Finance Corporation)
Mr. Johnson Chng Managing Director, Silk Road Finance Corporation
Mr. Patrick Ip Managing Director, China-ASEAN Investment Cooperation Fund
Mr. Ryoichi Nishizawa Global Head of M&A, Mitsubishi Corporation
Mr. Seth Sunderland Executive Director, Investment Banking, M&A Asia, UBS
Mr. Saurabh N. Agarwal Managing Director, Warburg Pincus
Mr. Hadi Cahyadi Managing Partner and Founder, Helios Capital
Mr. Kevin Murphy Managing Director, Andaman Capital Partners
Mr. Edwin Vanderbruggen Senior Partner, VDB Loi Co.,Ltd
Mr. Alex Kimura Chief Strategy Officer, Asia, Aviva
Mr. Sikh Shamsul Foreign Investment Division, Malaysian Investment Development Authority
Mr. Greg Ohan Director, Vietnam, Jones Lang LaSalle

and many more!

 

For Registration:

Event is organized by Valuetang LLC. For registration and enquiries please contact : charles.shangguan@valuetang.com and jenny.wang@valuetang.com

For partnerships, speaker and general business enquiries with 2iB Partners:

Contact Person Dylan Tan
Designation COO
Email Dylan@2ibpartners.com

YOU MAY LIKE

M&A – The Legal Angle

M&A - The Legal Angle The solution and problem in a merger or acquisition is regulatory in nature. In all cross-border deals, there is no go-around to regulations. Laws are enacted to essential protect life and property of its citizens. Therefore, it will...

read more

Why M&As Go Wrong

Acquisitions that are rushed can result in problems and challenges after closing in a transaction: Some of the reasons why M&As go wrong are:   1. Assumption Asymmetry Leaders and owners may over value a target by making assumptions including...

read more

Pin It on Pinterest